| Dr Donna L Musgrave, MD | |
|
21 Highland Ave Se, Ste. 200, Roanoke, VA 24013-2201 | |
| (540) 982-8881 | |
| (540) 982-0501 |
| Full Name | Dr Donna L Musgrave |
|---|---|
| Gender | Female |
| Speciality | Obstetrics/gynecology |
| Experience | 42 Years |
| Location | 21 Highland Ave Se, Roanoke, Virginia |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1588685648 | NPI | - | NPPES |
| 6243053 | Medicaid | VA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207V00000X | Obstetrics & Gynecology | 0101045444 (Virginia) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Carilion Medical Center | Roanoke, VA | Hospital |
| Lewisgale Medical Center | Salem, VA | Hospital |
| Carilion Franklin Memorial Hospital | Rocky mount, VA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Mid-atlantic Womens Care Plc | 8820998156 | 140 |
News Archive
Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited today announced the initiation of a Phase III clinical trial for TAK-700 in the U.S. in patients with advanced prostate cancer. TAK-700 is a selective, oral, non-steroidal androgen synthesis inhibitor that in preclinical studies has been shown to selectively bind to and inhibit the enzyme 17,20 lyase in both the testes and adrenal glands.
Angiotech Pharmaceuticals, Inc. today announced that on October 4, 2010, the Company was notified that QSR Holdings, Inc. as the representative for the former stockholders of Quill Medical, Inc. made a formal demand to the American Arbitration Association naming as respondents the Company, together with its subsidiaries QMI and Angiotech Pharmaceuticals (US), Inc.
In an exciting immunological medRxiv preprint paper, researchers from Germany and Russia analyzed adaptive immune response in severely affected patients with coronavirus disease (COVID-19). They demonstrated a protracted immune reaction characterized by egress of B lymphocytes into the blood.
Many tumors possess mechanisms to avoid destruction by the immune system. For instance, they misuse the natural "brakes" in the immune defense mechanism, which normally prevent an excessive immune response. Researchers at the University of Bonn have now been able to take off one of these brakes.
› Verified 9 days ago
| Entity Name | Mid-atlantic Womens Care Plc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1699365072 PECOS PAC ID: 8820998156 Enrollment ID: O20040115000607 |
News Archive
Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited today announced the initiation of a Phase III clinical trial for TAK-700 in the U.S. in patients with advanced prostate cancer. TAK-700 is a selective, oral, non-steroidal androgen synthesis inhibitor that in preclinical studies has been shown to selectively bind to and inhibit the enzyme 17,20 lyase in both the testes and adrenal glands.
Angiotech Pharmaceuticals, Inc. today announced that on October 4, 2010, the Company was notified that QSR Holdings, Inc. as the representative for the former stockholders of Quill Medical, Inc. made a formal demand to the American Arbitration Association naming as respondents the Company, together with its subsidiaries QMI and Angiotech Pharmaceuticals (US), Inc.
In an exciting immunological medRxiv preprint paper, researchers from Germany and Russia analyzed adaptive immune response in severely affected patients with coronavirus disease (COVID-19). They demonstrated a protracted immune reaction characterized by egress of B lymphocytes into the blood.
Many tumors possess mechanisms to avoid destruction by the immune system. For instance, they misuse the natural "brakes" in the immune defense mechanism, which normally prevent an excessive immune response. Researchers at the University of Bonn have now been able to take off one of these brakes.
› Verified 9 days ago
| Entity Name | Physicians To Women, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1679651715 PECOS PAC ID: 4880657063 Enrollment ID: O20041109000349 |
News Archive
Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited today announced the initiation of a Phase III clinical trial for TAK-700 in the U.S. in patients with advanced prostate cancer. TAK-700 is a selective, oral, non-steroidal androgen synthesis inhibitor that in preclinical studies has been shown to selectively bind to and inhibit the enzyme 17,20 lyase in both the testes and adrenal glands.
Angiotech Pharmaceuticals, Inc. today announced that on October 4, 2010, the Company was notified that QSR Holdings, Inc. as the representative for the former stockholders of Quill Medical, Inc. made a formal demand to the American Arbitration Association naming as respondents the Company, together with its subsidiaries QMI and Angiotech Pharmaceuticals (US), Inc.
In an exciting immunological medRxiv preprint paper, researchers from Germany and Russia analyzed adaptive immune response in severely affected patients with coronavirus disease (COVID-19). They demonstrated a protracted immune reaction characterized by egress of B lymphocytes into the blood.
Many tumors possess mechanisms to avoid destruction by the immune system. For instance, they misuse the natural "brakes" in the immune defense mechanism, which normally prevent an excessive immune response. Researchers at the University of Bonn have now been able to take off one of these brakes.
› Verified 9 days ago
| Entity Name | Mid-atlantic Womens Care Plc |
|---|---|
| Entity Type | Part B Supplier - Mammography Center |
| Entity Identifiers | NPI Number: 1699365072 PECOS PAC ID: 8820998156 Enrollment ID: O20080611000246 |
News Archive
Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited today announced the initiation of a Phase III clinical trial for TAK-700 in the U.S. in patients with advanced prostate cancer. TAK-700 is a selective, oral, non-steroidal androgen synthesis inhibitor that in preclinical studies has been shown to selectively bind to and inhibit the enzyme 17,20 lyase in both the testes and adrenal glands.
Angiotech Pharmaceuticals, Inc. today announced that on October 4, 2010, the Company was notified that QSR Holdings, Inc. as the representative for the former stockholders of Quill Medical, Inc. made a formal demand to the American Arbitration Association naming as respondents the Company, together with its subsidiaries QMI and Angiotech Pharmaceuticals (US), Inc.
In an exciting immunological medRxiv preprint paper, researchers from Germany and Russia analyzed adaptive immune response in severely affected patients with coronavirus disease (COVID-19). They demonstrated a protracted immune reaction characterized by egress of B lymphocytes into the blood.
Many tumors possess mechanisms to avoid destruction by the immune system. For instance, they misuse the natural "brakes" in the immune defense mechanism, which normally prevent an excessive immune response. Researchers at the University of Bonn have now been able to take off one of these brakes.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Donna L Musgrave, MD 21 Highland Ave Se, Ste. 200, Roanoke, VA 24013-2201 Ph: (540) 982-8881 | Dr Donna L Musgrave, MD 21 Highland Ave Se, Ste. 200, Roanoke, VA 24013-2201 Ph: (540) 982-8881 |
News Archive
Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited today announced the initiation of a Phase III clinical trial for TAK-700 in the U.S. in patients with advanced prostate cancer. TAK-700 is a selective, oral, non-steroidal androgen synthesis inhibitor that in preclinical studies has been shown to selectively bind to and inhibit the enzyme 17,20 lyase in both the testes and adrenal glands.
Angiotech Pharmaceuticals, Inc. today announced that on October 4, 2010, the Company was notified that QSR Holdings, Inc. as the representative for the former stockholders of Quill Medical, Inc. made a formal demand to the American Arbitration Association naming as respondents the Company, together with its subsidiaries QMI and Angiotech Pharmaceuticals (US), Inc.
In an exciting immunological medRxiv preprint paper, researchers from Germany and Russia analyzed adaptive immune response in severely affected patients with coronavirus disease (COVID-19). They demonstrated a protracted immune reaction characterized by egress of B lymphocytes into the blood.
Many tumors possess mechanisms to avoid destruction by the immune system. For instance, they misuse the natural "brakes" in the immune defense mechanism, which normally prevent an excessive immune response. Researchers at the University of Bonn have now been able to take off one of these brakes.
› Verified 9 days ago
Denise Marie Inman, DO Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 21 Highland Ave Se Ste 200, Roanoke, VA 24013 Phone: 540-982-8881 | |
Dr. Shannon Armbruster, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 1 Riverside Cir Ste 300m, Roanoke, VA 24016 Phone: 540-581-0160 | |
Dr. Elizabeth R Martin, M.D. Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 21 Highland Ave Se, Ste 200, Roanoke, VA 24013 Phone: 540-982-8881 Fax: 540-982-0501 | |
Steven Farber, MD Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 213 Mcclanahan St Sw, Roanoke, VA 24014 Phone: 540-343-1224 | |
Lauren Elizabeth Nelson, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 102 Highland Ave Se Ste 303, Roanoke, VA 24013 Phone: 540-985-9715 Fax: 540-985-8487 | |
Caroline Ludwig Welchman, MD Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 21 Highland Ave Se Ste 200, Roanoke, VA 24013 Phone: 540-982-8881 Fax: 540-982-0612 | |
Mark Arner, MD Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 102 Highland Ave Se, Roanoke, VA 24013 Phone: 540-985-9715 Fax: 540-985-9817 |